Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v11-FR Version v3-EN
Language French English
Date Updated 2020-05-29 2019-11-08
Drug Identification Number 02403188 02403188
Brand name CISPLATIN INJECTION CISPLATIN INJECTION
Common or Proper name CISPLATIN INJECTION CISPLATIN INJECTION
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients CISPLATIN CISPLATIN
Strength(s) 1.0MG 1.0MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 50 & 100ml 50 & 100ml
ATC code L01XA L01XA
ATC description OTHER ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date
Actual start date 2019-11-07 2019-11-07
Estimated end date 2020-09-30 Unknown
Actual end date 2020-05-27
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Teva is allocating and covering 30% of the market Teva is allocating and covering 30% of the market
Health Canada comments